Tesamorelin: A Narrow, Well-Defined Approval

The short version

Tesamorelin is a lab-made version of a hormone the brain already makes, called GHRH, which tells the pituitary gland to release growth hormone. Rather than supplying growth hormone directly, tesamorelin nudges the body into releasing more of its own — in a pattern closer to the body's natural rhythm than a straight growth-hormone injection would produce.

The FDA approved tesamorelin in 2010 for exactly one purpose: reducing excess abdominal fat in people with HIV-associated lipodystrophy, a fat-redistribution condition linked to antiretroviral treatment. That approval is narrow and specific — it does not extend to general fat loss, anti-aging use, or any use outside that one patient population, even though the peptide is studied more broadly. This page sticks to what has actually been shown.

What it is

As an active pharmaceutical ingredient, tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone, chemically modified at one end with a small hexenoic-acid group. That single modification is what makes it a viable drug: it blocks the enzyme that would otherwise break down natural GHRH within minutes, giving the synthetic version enough stability in the bloodstream to be clinically useful. It is supplied and dosed as the acetate salt.

How it works

Tesamorelin binds the GHRH receptor on growth-hormone-producing cells in the pituitary gland, triggering a signaling cascade that increases the pulsatile release of the body's own growth hormone. That growth hormone then drives the liver to produce insulin-like growth factor-1 (IGF-1), and together the two hormones promote fat breakdown that is preferentially concentrated in visceral fat — the metabolically active fat around internal organs, rather than fat just under the skin. Because tesamorelin amplifies an existing, naturally pulsatile hormone rhythm rather than replacing it with a constant external dose, its metabolic effects differ somewhat from directly injecting recombinant growth hormone.

What the research shows

Visceral fat and liver fat (2026 meta-analysis). Pooling five randomized controlled trials in HIV-associated lipodystrophy, tesamorelin reduced visceral adipose tissue by an average of 27.71 cm2 versus placebo, reduced trunk fat by 1.18 kg, reduced hepatic fat fraction by 4.28 percentage points, and increased lean body mass by 1.42 kg — all statistically significant, and without serious adverse events across the pooled trials ^[12].

Original JAMA trial. In 50 antiretroviral-treated adults with HIV, six months of tesamorelin 2 mg/day produced a treatment effect of -42 cm2 in visceral fat and a net -2.9% reduction in liver fat, both statistically significant ^[14].

Long-term data. Across a combined 52-week program of 273 people on tesamorelin versus 137 on placebo, visceral fat reduction was sustained at -18% relative to baseline, though blood-sugar parameters over the same period showed no clinically meaningful change; notably, fat reaccumulated once treatment was stopped ^[16].

Growth-hormone axis in healthy adults. In a small study of 13 healthy men, two weeks of tesamorelin measurably raised overnight growth hormone and IGF-1 levels without significantly affecting fasting glucose or insulin sensitivity ^[15].

Liver safety. The NIH's LiverTox database, drawing on the approval trials and post-market reporting, assigns tesamorelin its most reassuring likelihood category for drug-induced liver injury, noting no attributable liver-injury cases and no consistent liver-enzyme elevation in trials ^[13].

Cautions and open questions

Tesamorelin's own signed research corpus does not include a real-world patient-report dataset or a dedicated safety-caution list for this compound, so this section draws only on what the trial and regulatory record itself documents, rather than on community reporting.

The approval is genuinely narrow: it covers only HIV-associated lipodystrophy, and every other proposed use — general visceral-fat reduction, anti-aging, cognitive support — is off-label and has not been evaluated in the large controlled trials that support the approved indication. Visceral fat measurably returns once treatment stops, so any benefit depends on continued use rather than being a one-time correction ^[16]. Because tesamorelin raises IGF-1, a growth factor, and the approval trials ran for up to a year, long-term data on any cancer-related signal are limited; active malignancy is a labeled contraindication as a precaution. Tesamorelin is also a GHRH analogue and is prohibited in competitive sport at all times under the World Anti-Doping Agency's list of peptide hormones and growth factors — a regulatory fact distinct from any medical safety question, but a real constraint for tested athletes.

Where it fits in this hub

Tesamorelin is this site's case study in how specific a drug approval can be. It has real randomized-controlled-trial evidence behind it, unlike BPC-157 — but its FDA approval covers one condition, not the broad metabolic reach of semaglutide or tirzepatide. That gap between 'has trial evidence' and 'is approved for the use someone actually wants' is exactly what this hub's active-pharmaceutical-ingredient framing is built to make visible. See the comparison page for how all four line up.